@entity11358 is a useful and well-tolerated drug in the treatment of XXXX ( @entity829 ).

@entity1 @entity11358 @entity1017 @entity829 @entity110
Old generation H1-type antihistamines are the standard therapeutic option for @entity829 ( @entity829 ), but adverse effects are common. New antihistamines are well tolerated but efficacy is often poor. The present study aims to evaluate efficacy and safety of @entity11358 in the treatment of @entity829 @entity1 intolerant to old antihistamines and resistant to new drugs. We studied 14 @entity1 (4 males and 10 females). Mean duration of the disease was 48.9 (range 7-102) months. Cold cube test was positive in 78.6 % of @entity1 . Cold @entity110 was idiopathic in 10 (71.4 %) @entity1 . Cryoglobulins were detected in the serum of 4 cases (28.6 %). @entity11358 (25 mg t.i.d.) was administered for 3 months, and then it was gently tapered off and stopped within 2 months. A complete or good response was obtained in 8 (57.1 %) and 2 (14.3 %) @entity1 , respectively. Only two @entity1 were unresponsive (21.4 %). Tapering off or stopping @entity11358 was followed by the relapse of cold @entity110 in 7 cases (50.0 %). These @entity1 were amenable to a second treatment cycle. Six @entity1 (42.9 %) had a persistent remission. A @entity1 interrupted the therapy because of severe vertigo. Three @entity1 reported mild and transitory adverse effects including epigastralgia, @entity1017 and drowsiness. In conclusion, @entity11358 at high doses may be considered as an effective and well-tolerated treatment for @entity829 .
